Drug intelligence / Profile preview

human heterologous liver cells

Development stage: Unknown
Lead developer: Wake Forest Institute for Regenerative Medicine
Modality: Cell Therapies
Administration: Intraportal

Overview

Human heterologous liver cells are a type of stem cell derived from adult human liver donors for therapeutic use in others. These cells are isolated from healthy human livers and can be cryopreserved for later infusion. When administered via the portal vein, they can temporarily improve liver function in patients with metabolic disorders such as urea cycle disorders (UCDs). The cells demonstrate the ability to improve hyperammonemia and ureagenesis in individuals with severe UCDs, potentially serving as a bridge therapy until liver transplantation can be performed.

Other names: HHALPCHeterologous Human Adult Liver-Derived Progenitor CellsHeterologous human adult liver derived stem cellsHuman liver stem cells

Beyond the preview

Go deeper on human heterologous liver cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on human heterologous liver cells.

Explore the full profile